Sept. 18, 2024

Bionpharma issues voluntary nationwide recall of atovaquone oral suspension

At Prime Therapeutics Management, we want to help you receive the best possible care. Visit **PrimeTherapeutics.com/DrugRecalls** to review the latest FDA drug recalls.

About this recall:

Bionpharma is voluntarily recalling a single batch (lot) of atovaquone oral suspension, 750 mg per 5 mL (NDC 69452-0252-87) to the consumer level due to contamination with Cohnella bacteria. The product was manufactured by CoreRx and distributed by Bionpharma.

This product is an antimicrobial drug indicated for prevention of a certain type of infection known as Pneumocystis jirovecii pneumonia (formerly known as PCP for Pneumocystis carinii pneumonia) in adults and adolescents ages 13 years and older. The recall is for lot number 231003 with expiration date of September 2025. The lot number is listed on the side panel of the manufacturer's bottle or the bottom flap of the manufacturer's carton.

What this means to you:

In patients with a weakened immune system (immunocompromised patients), the potential exists that microbial contamination of atovaquone oral suspension could result in serious, life-threatening infections such as inflammation of the heart and permanent damage to soft tissue. To date, Bionpharma has not received any reports of adverse events related to this recall.

Consumers that have the recalled NDC and lot number should stop using the product and return to the place of purchase. Consumers with questions regarding this recall can contact Bionpharma by phone at **888.235.2466**, Monday–Friday, 9 a.m. to 5 p.m. Eastern Standard Time (EST) or via email at **DrugSafety@BionPharma.com**. Consumers should contact their health care provider if they have experienced any problems that may be related to taking or using the recalled lot of the drug.